ArticleMuscle & nerve2026
Administration of Schwann Cell-Like Cells Differentiated From Tonsil-Derived Mesenchymal Stem Cells Promotes Peripheral Nerve Regeneration by Inducing Macrophage Polarization in a Chronic Constriction Injury Model.
Article in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
INTRODUCTION/
aimsSchwann cell-like cells (TMSC-SCs) differentiated from human tonsil-derived mesenchymal stem cells (TMSCs) secrete many factors related to nerve regeneration. This study aimed to explore the potential of TMSC-SCs as a therapeutic agent for peripheral nerve regeneration using an animal model of chronic constriction injury (CCI) of peripheral nerves.
methodsIn this study, TMSCs or TMSC-SCs mixed with fibrin glue were administered to the sciatic nerves of CCI rats and observed for 2-8 weeks (Experiment 1). In addition, the mixture with fibrin glue and low- or high-dose TMSC-SCs (TMSC-SC-L or TMSC-SC-H) was administered to the same site and observed for 2-4 weeks (Experiment 2). After administration, peripheral nerve and gastrocnemius muscle regeneration and recovery of motor function were confirmed through nerve conduction studies and histopathological observations. The expression of M1 and M2 macrophage markers was examined after TMSC-SC treatment.
resultsBased on nerve conduction studies, myelination assessments, and gastrocnemius muscle observations, the TMSC-SC-H-treated group showed a significant regeneration effect compared with the TMSC or TMSC-SC-L-treated group. Additionally, compared to the TMSC-SC-L group (M1: 1.02 ± 0.15, M2: 0.73 ± 0.06), downregulation of M1 and upregulation of M2 macrophage markers were observed in the TMSC-SC-H group (M1: 0.47 ± 0.03, M2: 1.04 ± 0.11) by Western blotting. DISCUSSION: These results suggest that TMSC-SCs could be developed as an allogeneic therapeutic agent to improve peripheral nerve regeneration in patients with peripheral nerve injury. These findings could serve as a test method to address unmet clinical needs for peripheral nerve regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.